Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,895
  • Shares Outstanding, K 53,384
  • Annual Sales, $ 0 K
  • Annual Income, $ -134,850 K
  • EBIT $ -142 M
  • EBITDA $ -146 M
  • 60-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.25
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.60
  • Most Recent Earnings $-0.55 on 03/06/25
  • Next Earnings Date 05/08/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 81.89% ( -179.98%)
  • Historical Volatility 108.69%
  • IV Percentile 11%
  • IV Rank 12.27%
  • IV High 576.90% on 04/10/25
  • IV Low 12.65% on 10/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 2,767
  • Open Int (30-Day) 2,803

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.47
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.56
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +33.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4600 +19.57%
on 04/10/25
0.7999 -31.24%
on 03/18/25
-0.2336 (-29.81%)
since 03/17/25
3-Month
0.4600 +19.57%
on 04/10/25
1.8700 -70.59%
on 01/22/25
-1.1900 (-68.39%)
since 01/17/25
52-Week
0.4600 +19.57%
on 04/10/25
17.8250 -96.91%
on 05/07/24
-15.5300 (-96.58%)
since 04/17/24

Most Recent Stories

More News
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

ALXO : 0.5500 (-1.79%)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.5610 (-1.23%)
EXEL : 36.19 (+0.11%)
ONC.TO : 0.77 (-1.28%)
ALXO : 0.5500 (-1.79%)
CRDF : 2.85 (+1.42%)
VSTM : 5.74 (+15.73%)
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ALXO : 0.5500 (-1.79%)
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALXO : 0.5500 (-1.79%)
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

ALXO : 0.5500 (-1.79%)
ALX Oncology to Host Virtual R&D Day on March 5, 2025

ALXO : 0.5500 (-1.79%)
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALXO : 0.5500 (-1.79%)
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALXO : 0.5500 (-1.79%)
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

ALXO : 0.5500 (-1.79%)
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

ALXO : 0.5500 (-1.79%)

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 0.6067
2nd Resistance Point 0.5917
1st Resistance Point 0.5709
Last Price 0.5500
1st Support Level 0.5351
2nd Support Level 0.5201
3rd Support Level 0.4993

See More

52-Week High 17.8250
Fibonacci 61.8% 11.1916
Fibonacci 50% 9.1425
Fibonacci 38.2% 7.0934
Last Price 0.5500
52-Week Low 0.4600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar